[Functional neuroimaging in movement disorders]

Area of Science:

• Neurology
• Nuclear Medicine
• Neuroimaging

Background:

• Movement disorders, particularly Parkinson's disease, significantly impact patient management.
• Accurate differentiation between Parkinson's disease and parkinsonism-plus syndromes is crucial due to varying prognoses and therapeutic responses.
• The dopaminergic system's role in neurodegenerative disorders necessitates advanced imaging techniques for diagnosis.

Purpose of the Study:

• To highlight the contribution of functional imaging, specifically PET and SPECT, in managing movement disorders.
• To emphasize the utility of dopamine receptor and transporter imaging in diagnosing and differentiating neurodegenerative conditions.
• To showcase the role of these imaging modalities in monitoring disease progression and treatment effectiveness.

Main Methods:

• Utilizing Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) to assess regional cerebral metabolism and blood flow.
• Employing receptor ligands to visualize pre- and post-synaptic D2 dopamine receptors for differential diagnosis.
• Applying dopamine transporter ligands for early detection of Parkinson's disease risk.

Main Results:

• PET and SPECT imaging provide objective measures of cerebral function and dopaminergic system integrity.
• Dopamine receptor imaging effectively distinguishes idiopathic Parkinson's disease (presynaptic) from parkinsonism-plus syndromes.
• Dopamine transporter imaging enables early identification of individuals at risk for Parkinson's disease.

Conclusions:

• Functional imaging with PET and SPECT is indispensable for the comprehensive management of movement disorders.
• These techniques facilitate accurate diagnosis, differentiate between similar conditions, and monitor therapeutic interventions.
• PET and SPECT imaging are vital tools for assessing treatment efficacy, documenting surgical outcomes, and tracking disease progression in Parkinson's disease.